Home/Filings/4/0000899243-20-027297
4//SEC Filing

Arix Bioscience plc 4

Accession 0000899243-20-027297

CIK 0001664106other

Filed

Oct 4, 8:00 PM ET

Accepted

Oct 5, 5:00 PM ET

Size

26.1 KB

Accession

0000899243-20-027297

Insider Transaction Report

Form 4
Period: 2020-07-16
Transactions
  • Sale

    Common stock

    2020-07-17$9.24/sh31,101$287,3732,931,590 total(indirect: See footnote)
  • Sale

    Common stock

    2020-09-25$7.08/sh174,219$1,232,9482,655,020 total(indirect: See footnote)
  • Sale

    Common stock

    2020-07-16$8.56/sh16,332$139,7862,962,691 total(indirect: See footnote)
  • Sale

    Common stock

    2020-08-12$8.79/sh1,335$11,7352,867,912 total(indirect: See footnote)
  • Sale

    Common stock

    2020-09-28$7.54/sh273,584$2,061,8662,381,436 total(indirect: See footnote)
  • Sale

    Common stock

    2020-07-20$9.25/sh36,983$342,0562,894,607 total(indirect: See footnote)
  • Sale

    Common stock

    2020-07-22$9.00/sh22,651$203,9502,871,956 total(indirect: See footnote)
  • Sale

    Common stock

    2020-07-29$8.78/sh2,709$23,7882,869,247 total(indirect: See footnote)
  • Sale

    Common stock

    2020-08-13$8.75/sh159$1,3912,867,753 total(indirect: See footnote)
  • Sale

    Common stock

    2020-09-24$7.63/sh38,514$293,8232,829,239 total(indirect: See footnote)
Transactions
  • Sale

    Common stock

    2020-08-13$8.75/sh159$1,3912,867,753 total(indirect: See footnote)
  • Sale

    Common stock

    2020-09-24$7.63/sh38,514$293,8232,829,239 total(indirect: See footnote)
  • Sale

    Common stock

    2020-09-28$7.54/sh273,584$2,061,8662,381,436 total(indirect: See footnote)
  • Sale

    Common stock

    2020-09-25$7.08/sh174,219$1,232,9482,655,020 total(indirect: See footnote)
  • Sale

    Common stock

    2020-07-17$9.24/sh31,101$287,3732,931,590 total(indirect: See footnote)
  • Sale

    Common stock

    2020-07-16$8.56/sh16,332$139,7862,962,691 total(indirect: See footnote)
  • Sale

    Common stock

    2020-07-20$9.25/sh36,983$342,0562,894,607 total(indirect: See footnote)
  • Sale

    Common stock

    2020-07-29$8.78/sh2,709$23,7882,869,247 total(indirect: See footnote)
  • Sale

    Common stock

    2020-08-12$8.79/sh1,335$11,7352,867,912 total(indirect: See footnote)
  • Sale

    Common stock

    2020-07-22$9.00/sh22,651$203,9502,871,956 total(indirect: See footnote)
Footnotes (10)
  • [F1]Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $8.50 to $8.685 per share, inclusive. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission (the "SEC"), the Issuer, or a security holder of the Issuer.
  • [F10]Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $7.40 to $7.75 per share, inclusive. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the SEC, the Issuer, or a security holder of the Issuer.
  • [F2]These shares are owned directly by Arix Bioscience Holdings Limited, which is a wholly owned subsidiary of Arix Bioscience Plc. Arix Bioscience Plc is an indirect beneficial owner of the reported securities and disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. At the time of each reported transaction, the Reporting Person(s) owned greater than 10.0% of LogicBio Therapeutics, Inc.'s (the "Issuer") issued and outstanding common stock; however at the time of the filing of this Form 4 the Reporting Person(s) no longer hold 10.0% or more of the Issuer's issued and outstanding common stock.
  • [F3]Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $9.10 to $9.415 per share, inclusive. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the SEC, the Issuer, or a security holder of the Issuer.
  • [F4]Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $9.10 to $9.84 per share, inclusive. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the SEC, the Issuer, or a security holder of the Issuer.
  • [F5]Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $9.00 to $9.05 per share, inclusive. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the SEC, the Issuer, or a security holder of the Issuer.
  • [F6]Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $8.75 to $8.84 per share, inclusive. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the SEC, the Issuer, or a security holder of the Issuer.
  • [F7]Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $8.75 to $8.91 per share, inclusive. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the SEC, the Issuer, or a security holder of the Issuer.
  • [F8]Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $7.35 to $7.70 per share, inclusive. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the SEC, the Issuer, or a security holder of the Issuer.
  • [F9]Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $7.00 to $8.15 per share, inclusive. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the SEC, the Issuer, or a security holder of the Issuer.

Issuer

LogicBio Therapeutics, Inc.

CIK 0001664106

Entity typeother
IncorporatedUnited Kingdom

Related Parties

1
  • filerCIK 0001700449

Filing Metadata

Form type
4
Filed
Oct 4, 8:00 PM ET
Accepted
Oct 5, 5:00 PM ET
Size
26.1 KB